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Gap junctions are membrane structures made of intercellular channels which permit the diffusion from cytoplasm to cytoplasm of small
hydrophilic molecules. Nearly 40 years ago, the loss of functional gap junctions has been described in cancer cells and led to the hypothesis that
such type of intercellular communication is involved in the carcinogenesis process. From this time, a lot of data has been accumulated confirming
that gap junctions are frequently decreased or absent in cancer cells whatever their tissue and species origins. Here, we review such data by
insisting on the possible links existing between altered gap-junctional intercellular communication capacity (or the altered expression of their
constitutive proteins, the connexins) and the stages of cancer progression in various cancer models. Then, we analyse particular aspects of the
disturbance of connexin-mediated communication in cancer such as the cytoplasmic localization of connexins, the lack of heterologous
communication between cancer cells and normal cells, the role of connexin gene mutations in cancer. In a separate part of the review, we also
analyse the disturbance of gap-junctional intercellular communication during the late stages of cancer (invasion and metastasis processes).
D 2005 Elsevier B.V. All rights reserved.Keywords: Cancer; Carcinogenesis; Connexin; Gap junction; Gap-junctional intercellular communication
Contents. . . . . . . 126
. . . . . . . 130
. . . . . . . 130
. . . . . . . 130
. . . . . . . 130
. . . . . . . 131
. . . . . . . 132
. . . . . . . 132
. . . . . . . 132
. . . . . . . 132
. . . . . . . 132
. . . . . . . 132
. . . . . . . 133
. . . . . . . 1331. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2. Connexins and cancer progression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1. Connexin loss as an early event of cancer progression . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2. Liver cancer as a model of connexin-related cancer progression . . . . . . . . . . . . . . . . . . . . . . . .
2.2.1. Human liver cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.2. Rat liver cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3. Skin cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.1. Studies on murine and human skin tumors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.2. Studies on in vitro models of skin cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4. Bladder cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4.1. Studies on human material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4.2. Studies on rat material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.5. Oesophageal cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.6. Prostate cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .0005-2736/$ - s
doi:10.1016/j.bb
* Correspondi
E-mail addr1719 (2005) 125 – 145
http://wwwee front matter D 2005 Elsevier B.V. All rights reserved.
amem.2005.11.004
ng author. Tel.: +33 5 49 45 36 76; fax: +33 5 49 45 40 14.
ess: marc.mesnil@univ-poitiers.fr (M. Mesnil).
. . . . . . 133
. . . . . . 133
. . . . . . 134
. . . . . . 134
. . . . . . 134
. . . . . . 135
. . . . . . 135
. . . . . . 136
. . . . . . 136
. . . . . . 136
. . . . . . 136
. . . . . . 137
. . . . . . 137
. . . . . . 137
. . . . . . 137
. . . . . . 138
. . . . . . 138
. . . . . . 139
. . . . . . 140
. . . . . . 140
. . . . . . 140
M. Mesnil et al. / Biochimica et Biophysica Acta 1719 (2005) 125–1451262.7. Breast tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.8. Lung cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.9. Discussions about the models used. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. Aberrant gap-junctional intercellular communication and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1. Cytoplasmic localization of connexins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.1. Cytoplasmic localization of connexins in vivo . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.2. Cytoplasmic localization of connexins in vitro . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.3. Mechanisms leading to the aberrant localization of connexins . . . . . . . . . . . . . . . . . . . . .
3.2. Lack of heterologous gap-junctional intercellular communication . . . . . . . . . . . . . . . . . . . . . . . .
3.3. Connexin mutation and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.1. Cx37 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.2. Cx32 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.3. Cx43 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.4. Cx31.1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.5. Other aspects and conclusions about connexin gene mutation and cancer . . . . . . . . . . . . . . .
4. Connexins and metastasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1. Cell dissociation and invasion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2. Extravasation and formation of secondary tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.1. Connexin expression as a prerequisite for the loss of growth control . . . . . . . . . . . . . . . . . . . . . .
5.2. The effect of a lack of connexins on gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.3. General conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1411. Introduction
Gap junctions are present in all cell types of Vertebrates,
except very few cases such as red blood cells, platelets, some
neurons, mature skeletal muscle fibers and spermatozoids [1].
According to their ubiquity, it seems then reasonable, as it is
generally admitted, to consider that gap junctions are funda-
mental structures necessary for cell differentiation [2,3],
tissular physiology, and normal functions of the organs of the
body [1].
Verifying, at least, this very general statement, physiologi-
cally abnormal cells such as cancer cells, can be added to the
limited list of gap-junction deficient cells. Going through the
literature in this domain, it is first surprising to see that gap-
junction deficiency has been observed in cancer cells from a
large panel of tissue and species origin; an observation sup-
porting the general assumption that such a deficiency is
associated to the cancer phenotype [4–6]. However, by
considering precisely the literature, this general assumption
may look more complex and less homogenous than expected
depending (1) how gap-junction deficiency was defined and (2)
on which cell or tissue models the observations have been
carried out.
First, gap-junction deficiency has been defined in the
literature from either the lack of gap-junction plaques through
ultrastructural approaches (electron microscopy, freeze frac-
ture) to the lack of gap-junctional intercellular communication
(GJIC). GJIC itself has been defined with different meanings
depending on the technical approaches used for estimating its
capacity: electrical coupling, metabolic cooperation or dye-
transfer assay. In this last case, the size and the biophysical
properties of the tracers define the communication capacityeven if they do not have any metabolic role. We may then argue
about the concluding statement (lack of GJIC) when dye-
transfer assay has been used but not electrical coupling. We
may also argue about such a statement when the GJIC capacity
of cancer cells and normal cells from the same origin has not
been compared.
Secondly, it is legitimate to wonder whether it is possible to
compare the GJIC estimations obtained from very different
models such as in situ and ex vivo approaches or in vitro by
using primary cells and established cell lines. Similarly, is the
term ‘‘cancer’’ appropriate whatever we consider a sporadic
tumor in human, a chemically-induced tumor in animals,
primary cultures deriving from such tumors or established cell
lines? Moreover, in addition to these different ways of
estimating the GJIC capacity applied on these different (cancer)
models, we have also to consider the animal species from which
the tumor cells do originate. This last aspect is very important if
we keep in mind that a rodent cell is much easier to transform
and to become tumorigenic than a human cell. In other words,
do we really get similar conclusions by using human or animal
cells? However, despite these fundamental and important
questions, the large amount of in vitro and in vivo data which
has been accumulated do show that GJIC is frequently altered in
cancer cells whatever their tissue and species origins.
The story nearly started 40 years ago. It was in 1966 that
one of the first links between gap junctions and cancer was
established when Loewenstein and Kanno reported a lack of
electrical coupling in rat hepatomas. This phenomenon was
observed in both chemically-induced hepatomas as well as in
Morris and Novikoff’s rat transplanted hepatomas [7,8]; a
situation which was completely different from the well-coupled
normal liver cells [9]. Then, similar results were observed in
Table 1
Studies of the expression and/or function of connexins in various human tumor samples (tissue, primary cultures, cell lines)
Organ/tissue Pathology Study GJIC Cx expression Reference
Bladder Normal urothelial
cells
Cell lines + (Scrape loading) Cx26 and Cx43 (Northern); [19]
Cx26 j (mRNA) in confluent cultures [19]
Cancer Cell lines  Cx26 , (mRNA) [20]
Normal urothelium Tissue NTa Cx26b (punctuate
staining in basal layer)
[20]
Tissue NT Cx26 , (70% of tumors)
Low grade
non-invasive
Tissue NT Diffusely expressed (28%)
Tissue NT Heterogeneous loss of expression (44%)
Tissue NT Extensive loss of
expression (28%)
High grade
(invasive)
Tissue NT Diffuse expression (32%) [19]
Tissue NT Heterogeneous (41%)
Tissue NT Extensive (27%)
Brain Epilepsy Primary culture High (FRAP)c Cx43 (intense) [21]
Low-grade
astrocytomas
Primary culture Moderate (FRAP) Cx43 , (moderate intensity) [21]
Glioblastoma
multiforme
Primary culture Lowest (FRAP) Cx43 , (low levels) [21]
Glioma
(Grades I and II)
Tissue NT Cx43 (intense) [22,23]
Glioma (Grade III) Tissue NT Cx43 (very weak)
Glioma (Grade IV) Tissue NT Cx43 (almost not detectable) [22,23]
Breast Normal Tissue NT Cx26 () [24]
Cx43 (punctuate staining in
myoepithelial cells)
[24]
Benign lesions Tissue NT Cx43 (punctuate staining in
myoepithelial cells)
[24]
Ductal carcinoma Tissue NT Cx43 (punctuate staining in
myoepithelial cells)
[24]
Lobular carcinoma Tissue NT Cx26 (), Cx43 () [24]
Mucoid carcinoma Tissue NT Cx43 (punctuate) [24]
Invasive carcinomas Tissue NT j Cx26 (cytoplasmic
staining + heterogeneous:
15/27 samples);
[24]
Cx43 (in stromal cells:
27/27 samples;
heterogeneous expression
in carcinoma cells and
intracellular: 14/27 samples)
[24]
Normal Tissue NT Cx43 (+) [25]
Infiltrated and
non-infiltrated
ductal carcinoma
Tissue NT Cx43 () [25]
Infiltrated and
non-infiltrated
carcinoma
Tissue NT Cx43 () [25]
Carcinoma Cell lines NT Cx43 () (4/6 cell lines by
Western and Northern)
[25]
Cervix Normal Tissue NT Cx43 [26]
Dysplastic regions Tissue NT Cx43 , [26]
Endometrium Normal Tissue NT Cx26 and Cx32d [27,28]
Hyperplasia Tissue NT Cx26 and Cx32 [27,28]
(Weak or negative; 73–80%;
Diffuse expression in
cytoplasm: 20–27%)
Cx43 (weak) [27,28]
Cancer Tissue NT Cx26 and Cx32 [27,28]
(Weak or negative: 76–79%;
Diffuse: 15–18%; Normal: 6%)
Cx43 (weak) [27,28]
(continued on next page)
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Table 1 (continued)
Organ/tissue Pathology Study GJIC Cx expression Reference
Head and neck Squamous cell
carcinomas
Primary cells NT ,Cx31.1 (cDNA microarray) [29]
Larynx Normal Tissue NT Cx26, Cx30, Cx43e [30]
Squamous cell
carcinoma
Tissue NT Cx26, Cx32, Cx43
(Heterogeneous expression)
[30]
Liver Normal Tissue +f Cx32 (+), Cx26 (+), Cx43 () [31]
Hepatocellular
carcinomas
Tissue ,f Cx26 ,/Cx32=cytoplasmicg [31,32]
Cx43 j (cytoplasmic) [31,33]
Lung Normal Tissue NT Cx26 (), Cx32 (), Cx43 (+) [32]
Carcinoma Cell line ,h Cx43 ,i [34]
Small-cell carcinoma Tissue NT Cx26 j, Cx32 (), Cx43 , [32]
Non-small cell
carcinomasj
Tissue NT Cx43 , Cx32 () poorly
differentiated
[35]
Freshly explanted
tumor cells
k NT [35]
Cell lines k NT [35]
Oesophagus Normal Tissue NT Cx26 Cx43 (NT) [36]
Cx26l and Cx43l [37]
Cx26 and Cx43 [32]
Squamous-cell
carcinoma
Tissue NT Cx26 ,m and Cx43 ,m [32]
Ovary Normal Primary culturesn Extensiveh Cx43 (Cx26, 32, 37, 40:
not detected)
[38]
Tissue NT Cx43 cytoplasmic and
punctated Cx26 (), Cx32 ()
[38,39]
Adenocarcinoma Cell lines None or littleh None [39]
Cx43 (Northern and western)
(stained positively: 59%)
Ovarian endometrioid
adenocarcinomas
Tissue NT j Cx43 mRNAo [40]
Serous
cystadenocarcinomas
Tissue NT Cx43 (,) Cx26 (), Cx32 ()
(19% stained positively for Cx43)
[38]
[39]
Prostate Normal Tissue NT Cx26() Cx32() Cx43(+) [32]
Benign tumors Tissue NT Cx26 (NT) Cx32 (NT) Cx43(+) [41]
Cancer Tissue NT Cx26 (NT) Cx32 (NT) Cx43, [41]
Normal Tissue NT Cx32 in cell –cell contact areas [42]
Tumors Tissue NT Cx32 Cx43 in cell –cell contact areas
(differentiated tumors) cytoplasm
and loss in advanced stages
(undifferentiated tumors)
[42]
Normal Tissue NT Cx43: basal epithelial cells
Cx32: luminal epithelial cells
[43,44]
[43,44]
Benign prostatic
hyperplasia
Tissue Cx32 j and Cx43 j
(Increase of incidence and
intensity in epithelial cells)
[43,44]
Cancer Tissue NT Cx43 (): 65% [43,44]
Cx32 (): 38%
Cx43 () Cx32 (): 28%
In poorly
differentiated cancer
Cx43 (): 90%
Cx32 (): 60%
[43,44]
Normal Cell lines +h Cx32 Cx40 transcripts [45]
Malignant Cell lines p Cx43 transcripts GJIC [45]
Non-tumorigenic Cell lines p Cx43 [46]
Malignant Cell lines h Cx43 [46]
Normal Epithelial
primary cells
+h Cx43 [47]
Tumor Cell lines h , Cx43 (impaired
post-translational
modification)
[47]
Skin Normal Tissue NT Cx43q [48]
Basal cell carcinoma Tissue NT Cx43 ,r [48]
Squamous cell
carcinoma
Basal cell carcinoma Tissue NT Cx43 , and Cx26 js [32]
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Table 1 (continued)
Organ/tissue Pathology Study GJIC Cx expression Reference
Testes Testes infiltrated Tissue NT Cx43 Cx26 () [49]
Testes infiltrated
with carcinoma in situ
Tissue NT Cx43 () [49]
Testes infiltrated
with seminoma
Tissue NT Cx26 (cytoplasmic) [49]
Thyroid Normal Tissue NT Presence of GJ (Freeze-fracture) [50]
Oncocytic adenoma Tissue NT No GJ
Oncocytic carcinoma Tissue NT No GJ
Papillary carcinoma Tissue NT Presence of GJ
a NT: not tested.
b When there is no indication on the techniques used the expression of connexins was studied by immunocyto(histo)chemistry or immunofluorescence, and the
connexins are expressed.
c FRAP: Fluorescence Recovery After Photobleaching.
d Expression fluctuating during the phases of the reproductive cycle. Weak expression during the proliferation phase.
e Cx26 and Cx30 detected in parabasal and intermediate layers of the laryngeal epithelium. Cx43 detected in parabasal, basal and lower layers.
f Lucifer yellow transfer assay performed on fresh surgically removed samples.
g Only deficiency in normal punctate Cx32 and Cx26 staining was observed with altered localization of these proteins in some tumors.
h Microinjection of Lucifer yellow.
i Compared to non-transformed lung epithelial cells.
j Adenocarcinomas and squamous cell carcinomas.
k Estimation of GJIC by electroporation.
l Cx26 is specifically detected in the basal and intermediate layers of the squamous epithelium of esophagus. Similar but weaker pattern was observed for Cx43.
Cx32 was not detected.
m Cx26 and Cx43 were coexpressed and confined to small areas in the tumor, whereas most parts of the tumors did not show any specific labeling. No significant
decrease was observed between the primary tumor and the lymph-node metastasis [30].
n 2–4 passages of surface epithelium.
o Associated with deregulation of h-catenin.
p Scrape loading and FRAP.
q Cx43 was detected by immunoelectron microscopy and classical immunofluorescence. The expression varied according to the skin layers (weak expression in
basal layer, increased expression in spinous layer and negative in horny layer).
r Small number of small gap junctions and cytoplasmic localization of the Cx43 (immunofluorescence and immunoelectron microcopy).
s Immunoflurescence heterogeneity of the Cx26 staining which looks more pronounced at the periphery of the tumors.
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example of this period came from human carcinoma of the
stomach in which no electrical coupling was detected [11].
Already, in this short period of time, the same phenotype
(lack of electrical coupling) appeared to be a common
characteristic of solid tumors differently induced (chemically,
transplanted or spontaneous) and originating both from
various Mammal species (human, rat, hamster) and unrelated
tissues (liver, thyroid, stomach). This first panel of data,
coming from Loewenstein’s laboratory and colleagues,
established tumors, or cells derived from tumors, as
communication deficient contrary to their normal counter-
parts. Since the most obvious phenotypic aberration of tumor
cells is a deregulated growth, all these observations are at the
origin of the general assumption that gap junctions are
involved in cell growth control. The hypothesis linking lack
of GJIC and cancer has been consigned in a review by W.
Loewenstein himself [4]. Then, such an hypothesis has been
reinforced by giving a more active involvement in carcino-
genesis to gap junctions once tumor-promoting agents were
found to be inhibitors of this type of cell-to-cell communi-
cation [12–15].
Now, it is known that the gap-junction channel (about 15 A˚
diameter) is expected to permit the cell-to-cell transmission of a
wide range of cellular molecules (inorganic ions, metabolites,high-energy phosphates, nucleotides, cyclic nucleotides, sec-
ond messengers, etc.) [16,17]. A priori, it would not be
surprising to consider that such an ubiquitous and ancient
intercellular channel adapted, through the Vertebrate evolution,
to a wide variety of cellular functions involving the intercel-
lular transfer of molecules; one of these functions being the
intercellular transmission of growth-regulating signals. Forty
years after the original observations, the hypothesis associating
lack or diminished gap junctions and cancer is still valid and
developing with new emerging concepts like the possible
involvement of stem cells and their GJIC capacity in
carcinogenesis [18].
In order to understand better how do gap junctions are
involved in carcinogenesis, several in vitro and in vivo analyses
then attempted to describe an association between disturbed
connexin expression and particular stages of cancer progression.
A review of such studies performed on human cancer materials
is presented in Table 1. The object of this article is to review first
such data not only obtained from human but also animal
materials by insisting on the possible links that can be
established between altered GJIC and the stages of cancer
progression. Then, some particular aspects linking GJIC and
cancer will be analysed such as the cytoplasmic localization of
the connexins, the lack of homologous and heterologous
communication among cancer cells, mutation of the connexin
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processes.
2. Connexins and cancer progression
An important fact to consider is whether the decrease of
GJIC and/or connexin expression do follow the cancer
progression. If such a relationship does exist, it may mean
that connexins are involved in the carcinogenesis process; the
progressive loss of GJIC favorizing the tumor progression.
2.1. Connexin loss as an early event of cancer progression
If a decreased expression of connexins has been often
claimed in carcinogenesis; it is difficult to indicate at which
step of the multistage process it really does occur. It has been
suggested that tumors may derive from the clonal expansion of
an adult stem cell that either does not express connexins or is
sufficiently differentiated to express them. The first situation
would explain why the cells do not communicate from the very
early stages of tumorigenesis. The second situation would
illustrate why cancer cells do express connexins at the early
stages of carcinogenesis; the level of expression and/or function
of connexins being then decreased by the onset of oncogenic
activations at later stages of tumor progression. This so-called
stem-cell concept has been extensively reviewed elsewhere [18].
In some cases, the decreased expression of connexins
indeed seems to be an early event, occurring in dysplastic
cells of precancerous lesions; which is hypothesized to
contribute to their neoplastic progression. This is the case for
Cx43 which is highly reduced in the dysplastic regions of the
human cervix compared to the normal tissues [26]. Hyperplasia
of endometrium also exhibits such an abnormal expression for
Cx26 and Cx32 [28]. Similarly, the lack of detection of gap
junctions by freeze fracture in thyroid tumors whatever their
stages (adenomas and carcinomas) argues for an early event
favorizing the clonal expansion of abnormal cells towards
cancer [50].
An interesting example illustrating that a disturbed expres-
sion of connexins might be a prerequisite for human cell
expansion could be kidney. Indeed, hemodialysis patients with
end-stage renal disease have an increased incidence of renal
cell carcinoma compared to the general population. Hyper-
methylation of CpG islands of the Cx32 gene has been
observed in both cancerous and non-cancerous regions of the
kidney from such patients. Since hypermethylation of the Cx32
gene occurred only in cancers lesions from patients of the
general population, the consequent lack of expression of Cx32
would be related, or even a prerequisite, to the early stage of
renal carcinogenesis [51]. However, if the decreased expression
of connexins or the lack of gap junctions at early stages
(adenomas or even dysplastic region of precancerous lesions)
has been observed in a wide range of tissues, it cannot be a
‘‘general law’’. As it is often the case, the situation is more
complicated and depends on the tissue which is considered.
For instance, in the larynx, no obvious difference of
connexin expression has been reported; Cx26 (in parabasaland intermediate layers), Cx30 and Cx43 (in basal, parabasal
and lower layers) have a similar level of expression in normal
tissue and in precancerous lesions [30]. On the contrary, an
hyperexpression is even observed in some dysplastic lesions of
the larynx [30]. The aberrant expression was observed in later
stages (squamous cell carcinomas) and characterized by a
heterogenous staining for these connexins (regions with
intensive expression alternated with region of no expression).
In prostate, the decrease of Cx43 is more obvious in the late
stages but not in the benign stages [41]. This would mean that
the decreased Cx43 expression is not involved in the initiation
of prostate cancer [41]. This hypothesis is reinforced by the fact
that there is a marked increase in incidence and intensity of
Cx43 immunostaining in benign prostatic hyperplasia [43,44].
A similar observation was made about Cx43 in human gliomas:
three different studies reported so far a diminished expression
of Cx43 which correlates with the progression of the tumors
[21–23].
2.2. Liver cancer as a model of connexin-related cancer
progression
Liver cancer is an interesting model for studying the
possible involvement of connexins in cancer. Indeed, well-
established protocols of chemically-induced liver cancer in
rodents have been known for long and provided a cancer-
progression model exhibiting well-defined stages. Since liver
was known to be a well-coupled tissue, expressing at least
two major connexins (Cx26 and Cx32), it has been
extensively used to reveal any putative correlation between
connexin disturbance and fundamental steps of liver carcino-
genesis. Moreover, since liver tissue is pretty homogenous
and soft, it became possible to perform ex vivo dye-transfer
assays [52]. Such a functional approach permitted to have a
rather complete set of tools not only for studying the function
(ex vivo microinjection of fluorescent tracers) but also the
fluctuation of expression at the mRNA and protein levels
(Northern and Western analysis) and the localization (immu-
nohistochemistry) of connexins during each of the well-
defined stages of chemically-induced rat hepatocarcinogen-
esis. Finally, it was possible to use the same tools for human
liver tumors in order to see if any disturbance of GJIC could
be a general phenomenon independently of the considered
species.
2.2.1. Human liver cancer
First, if we consider human liver cancer, connexin expres-
sion might be thought to not be a good marker of cancer
progression since the decreased GJIC capacity which is in
adenomas as strong as in carcinomas is not accompanied by a
decreased expression of the connexins [31,33]. However, it is
different if we consider the localization of Cx32; in adenomas
it is detected in parts of the plasma membrane in contact with
neighboring cells contrary to hepatocellular carcinomas in
which Cx32 is mostly localized in the cytoplasm [31]. In
addition to this aberrant expression and/or localization of the
original connexins, another disturbance concerns the newly
M. Mesnil et al. / Biochimica et Biophysica Acta 1719 (2005) 125–145 131synthesized cytoplasmic and non-phosphorylated form of Cx43
in the invasive parts of human liver. The newly expression of
Cx43 in hepatocellular carcinomas can be the sign of a
‘‘dedifferentiation process’’. On the other hand, it can be also
due to the presence of liver stem cells (oval cells) which are
known to express Cx43 [18,53]. However, a study evoked the
presence of both Cx32 and Cx43 in the cytoplasm and in the
plasma membrane of normal human liver [54]. Despite this
fundamental difference with other studies showing no detection
of Cx43 in normal human liver, both connexins were found to
be markedly decreased by these authors in the hepatocellular
carcinomas at a post-translational level [54].
2.2.2. Rat liver cancer
2.2.2.1. Early stages of rat liver cancer. The picture is clearer
for rat liver carcinogenesis. An early and progressive decreased
expression of connexins is clearly observed in chemically-
induced liver tumors. In rats, Cx32 mRNA is decreased in
hyperplastic nodules induced by N,N-diethylnitrosamine
(DEN) or N-ethyl-N-hydroxyethylnitrosamine (EHEN) treat-
ments. It is barely detectable in further stages such as
hepatocellular carcinomas [55]. When the function of gap
junctions was tested by microinjecting fluorescent tracers such
as Lucifer yellow, it was clear that the loss of Cx32 mRNA is
accompanied by the decrease of GJIC. In such an experimental
model, the decrease of GJIC appears to be an early event which
is already obvious 4 weeks only after the beginning of the
chemical treatment before the apparition of the focal lesions.
Interestingly, the decreased GJIC capacity appeared before the
decrease of the number of Cx32 spots as detected by
immunohistochemistry meaning that a conformational change
of Cx32 connexons could have been induced via phosphory-
lation by the treatment [52]. Most enzyme-altered (glutathione
S-transferase placental form positive: GST-P positive) focal
lesions showed lower GJIC and lower Cx32 spots than
surrounding hepatocytes leading probably to a lack of
heterologous communication which could emphasize the clonal
expansion of such lesions.
An interesting observation is that if Cx32 mRNA is
decreased in cells of the primary tumors induced chemically,
the immunocytochemical analysis revealed a decrease in gap
junctions in some but not all preneoplastic focal lesions [56].
Others described similar facts: only a small part (17%) of the
GST-P positive foci were found to have a marked reduction of
Cx32 gap junctions in rats; this decrease being more important
in hyperplastic nodules [57]. Not such a relation was found for
Cx26 which seems to be differently regulated at least in the
first step of liver carcinogenesis. It is more expressed in some
of the GST-P positive foci (44%) and in a small part of the
hyperplastic nodules (16%) [57]. Similarly, most preneoplastic-
altered foci generated by DEN initiation and phenobarbital or
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) promotion exhib-
ited a decreased Cx32 or an increased Cx26 staining; Cx43
being not detected [58]. Interestingly, the hyperexpression of
Cx26 might be related to cell proliferation since Cx26 is
enhanced in hepatocytes before the onset of S-phase afterpartial hepatectomy in rats [59]. Therefore, the Cx32 decrease
is an early event in induced rat liver carcinogenesis; this
conclusion is reinforced by the fact that the quantity of Cx32
spots is decreased after partial hepatectomy, a promotion stage
of rat liver carcinogenesis. This decrease is probably due to a
lower amount of Cx32 mRNA [59].
This observation may tend to indicate that the focal lesions
exhibiting a low level of gap junctions are the precursors of the
primary tumors; these primary tumors keeping a low level of
gap junctions. If this scenario is true, it means that in the rat
liver, the loss of gap junctions is a prerequisite for the further
development of primary tumors. Such a picture might be a
correct one since Cx32-knock out mice do present a higher
level of both spontaneous and chemically-induced liver tumors
[60]. Similarly, the highest sensitivity of female rats than males
to hexachlorobenzene is related to a lower amount of Cx32
mRNA (8 fold lower in females than in males) [61].
2.2.2.2. Late stages of rat liver cancer. A progressive
decrease of Cx32 expression is often observed from early
preneoplasia (enzyme-altered foci) to hyperplastic nodules and
hepatocellular carcinoma (no Cx32 is even detected in
pulmonary metastatic hepatocellular carcinomas). Since there
is an inverse correlation with an increase BrdU index, the
observed decrease appears linked to the cell proliferation and
progression of hepatocarcinogenesis [62]. The fact that the
number of Cx32 positive spots per mm2 is significantly less in
hepatocellular carcinoma than in surrounding non-carcinoma-
tous cirrhotic tissues [63] may suggest that the Cx32 loss
provides a cellular independence and a growth advantage to
tumor cells [62].
The deficiency of normal punctuate Cx32 staining may not
be related to a loss of Cx32 mRNA but rather to an altered
localization of the protein in some tumors [58]. In this last case,
Cx32 exhibited some altered electrophoretic mobility suggest-
ing that post-translational modifications are responsible for the
altered localization. In some tumors, Cx32 mRNA was
detected without corresponding Cx32 immunoreactivity, indi-
cating that some hepatomas downregulate Cx32 independently
of mRNA abundance [58]. This tends to show that several
pathways may lead to a decreased level of GJIC which seems
to be the common, final and crucial event, tightly controlled by
the level of Cx32 mRNA expression, the post-transcriptional
expression of Cx32, the localization of this connexin and
possibly its phosphorylation state. These different levels of
alteration of the Cx32 might be related to the rat strains or the
treatments.
However, if Cx32 expression and/or function are highly
related to the progression of rat hepatocarcinogenesis, we do
not know how Cx32 does control cell proliferation. Cx32-KO
mice exhibit a higher rate of liver tumors than wild-type mice
[60]. Apparently, in these Cx32-KO mice, the amount of Cx26
is also decreased in the hepatocytes [60] up to a level which is
probably not sufficient for suppressing the tumor growth.
Recent observations have shown that Cx32 expression is
needed for the initiation of synchronous DNA synthesis in
hepatocyte nuclei after partial hepatectomy [64]. Since cAMP-
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regeneration in partially-hepatectomized rats [65], this syn-
chronous activation of quiescent hepatocytes could be achieved
by equilibrating second messengers (cAMP or IP3) among
cells. Interestingly, CREM-deficient mice exhibit a significant
reduced cell proliferation during liver regeneration [66].
Despite the fact that Cx26 is also decreased in hepatocellular
carcinomas [57], it seems reasonable to postulate that Cx32 and
Cx26 are differentially regulated during the progression of rat
liver carcinogenesis. First, the amount of Cx32 is apparently
decreased earlier than Cx26. Second, the onset of tumorigen-
esis is related to both a decrease of Cx32 expression and/or cell
communication function and an increase of Cx26 expression
(possibly at the S-phase of the cell cycle). Since the Cx26
overexpression does not seem to counteract on the communi-
cation capacity, we may postulate that the two connexins have
different roles concerning their involvement in the regulation of
communication in liver; Cx32 loss is clearly related to GJIC
loss, independently of Cx26 expression.
2.3. Skin cancer
In skin, most extensive studies on connexin expression have
been performed on the mouse model. These studies were
mostly focused on the behaviour of Cx26 and Cx43 which
have been thought for long time to be the major connexins of
the skin tissue. Now, we know that the expression pattern of the
connexins in skin is very complicated and concern other types
of connexins which have been identified in more recent years.
For these reasons, the ‘‘picture’’ of connexin expression related
to skin carcinogenesis is not complete and still need further
studies both in animal models and in human tissues.
2.3.1. Studies on murine and human skin tumors
In mouse skin, the pattern of expression of Cx26 and Cx43 is
clearly segregated: Cx43 is predominantly expressed in the less
differentiated lower spinous layers of the normal skin whereas
Cx26 is more present in the terminally differentiating upper
spinous and granular layers [67]. The particular pattern of
expression of Cx26 and Cx43 does not seem to be altered in the
hyperplastic epidermis. It starts to be modified from the
papillomas stages and follows two fundamental steps: (1) a
loss of segregation in papillomas (both Cx26 and Cx43 are
localized in the lower spinous layers); (2) a loss of detection in
the squamous cell carcinomas [67]. The decrease of Cx26 and
Cx43 expressions is apparently related to the progression stages
of the tumors from papillomas to well-, moderately- and poorly-
differentiated squamous cell carcinomas of the skin induced
chemically [68]. If a loss of segregation of expression is
commonly observed for Cx26 and Cx43 in papillomas [67,68],
some found an overexpression at this stage [69]. However, in
late papillomas, a local loss of Cx26 immunostaining can be
observed [69]. Then, the decrease of both connexins seems to be
the consequence of a post-translational phenomenon since
mRNA is still present [69]. Very few is known about the other
connexins which are also present in the skin: a strong inhibition
of Cx31.1 during all stages has been reported [69] but morestudies are needed to complete the ‘‘connexin scenario’’ during
chemically-induced skin carcinogenesis in mice.
Moreover, we have to consider that the rare studies on
connexin expression which have been performed on human
biopsies did not report a so clear picture. Apparently, Cx43 is
poorly present in squamous cell carcinomas [48]. This is also
the case in the basal cell carcinomas contrary to Cx26 which
was even found to be more expressed in the human basal cell
carcinomas than in the normal epidermis [32,48].
2.3.2. Studies on in vitro models of skin cancer
Cell lines and primary cultures from different stages of mouse
skin carcinogenesis have been used to estimate whether the GJIC
capacity is related to the progressive stages of cancer progres-
sion. In general, it has been reported a good correlation between
the decrease of GJIC capacity (often tested by Lucifer yellow
microinjection) and the progression of skin cancer [70,71].
However, such in vitro approaches have to be considered
carefully since the establishment of cell lines may denaturate
the original properties of the tumor cells. This may explain why
no significant difference of GJIC was found sometimes
between cell lines from normal keratinocytes, papillomas or
squamous carcinomas [72]. Actually, for this last report, a
marked decrease (80–90%) in GJIC was found on progression
from squamous to spindle carcinoma cells. E-cadherin seems to
be involved in the regulation of GJIC in such cells by
permitting or not, depending on their level of expression, the
correct addressing of the connexins towards the cell membrane
[72,73].
2.4. Bladder cancer
2.4.1. Studies on human material
As for the two previous kinds of cancer (liver and skin), two
connexins have to be considered: Cx26 and Cx43. Contrary to
these two previous examples, the correlation between the
connexin behaviour and the progression stage of the bladder
cancer is not so clear and looks confusing depending on the
models used. By considering human cancer cells lines, a loss of
Cx26 expression has been associated with the malignant
phenotype contrary to Cx43whose variable expression in cancer
cell lines is not related to the GJIC capacity [19]. The expression
of Cx26 is decreased but heterogeneously in situ without any
clear difference between non-invasive and invasive cancers [20].
However, others have found that Cx43 expression and GJIC
capacity of human uroepithelial cells are inhibited by the
exposure to a tobacco-related nitrosamine [74]. Interestingly,
the expression at the protein level of Cx43 is recovered within 24
h of removal of the carcinogen [74]. According to these results,
Cx43 could play a major role at the very precancerous stages and
Cx26 a more crucial role at the following steps of cancer
progression but the data are too parcellar to make such a
conclusion as a definitive one.
2.4.2. Studies on rat material
Bladder carcinoma cells from rats present contradictory
results compared to the human model. In such cells, there is a
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capacity (due to higher levels of Cx26 or Cx43 mRNAs) were
the most tumorigenic. These results were similar to those
obtained from in situ studies. In rat bladder, Cx43 is barely
detectable and Cx26 is not. However, in rat bladder carcino-
mas, mostly in N-ethyl-N-(4-hydroxybutyl)nitrosamine
(EHBN)-induced carcinomas, abundant expression of the two
types of connexins was observed. It was even concluded from
these studies that increased GJIC capacity or increased
connexin expression may give a growth advantage in rat
bladder carcinogenesis [75].
2.5. Oesophageal cancer
If there are contradictory observations for a same kind of
cancer, such as bladder cancer, depending on the considered
species, there are also cases, such as oesophageal cancer, for
which the same connexins (Cx26 and Cx43) expression and/or
function do not exhibit any correlation with cancer progression.
No drastic loss of connexin expression was found in squamous
cell carcinomas of the human oesophagus [32]. Cx26 and Cx43
were still detected immunohistochemically but the only
difference was on the heterogenous staining: some parts of
the tumors exhibiting a normal staining and other parts without
any staining. This heterogeneity was not modified according to
the tumor phase since it was also found in metastasis. It has
been suggested that such a heterogeneity of connexin
expression could be the consequence of cancer stem cells
present within the tumors with their partially-differentiated
daughter cells [18].
However, this apparently lack of correlation between
connexin expression and the progression stage of the tumor
is related to what is observed in cell lines; in such cells the level
of expression does not correlate perfectly with tumorigenicity
[37]. Such a lack of correlation was also observed in rat cells;
both non-tumorigenic and tumorigenic oesophageal cell lines
exhibited high level of dye coupling and comparable levels of
Cx43 expression [76].
2.6. Prostate cancer
The picture is clearer for human prostate cancer in which
Cx32 and Cx43 expressions have been studied. The decrease of
expression for both connexins is obvious in the carcinomas and
even stronger in the poorly-differentiated tumors [44]. The
study realized by Mehta was more precise since he reported,
with his colleagues, a correct localization of the two connexins
in well-differentiated tumors and a more cytoplasmic localiza-
tion in the undifferentiated ones with an eventual loss of
expression in advanced stages [42]. If this is true, it would
mean that these connexins do not play a role at the beginning of
the progression of prostate cancer. Interestingly, more doubt
concerns the expression of the connexin in the normal tissue.
Some only found Cx32 detectable [42] when others found a
segregated expression of Cx32 (in luminal cells) and Cx43 (in
basal cells) [44]. In the first case, Cx32 was detected in the
tumors, meaning that its expression (like Cx43 for liver cancer)would be associated with the dedifferentiation of the tissue.
More studies are necessary in order to have a better picture of
the connexin expression pattern in human prostate cancer.
2.7. Breast tumors
In human breast, the expression and localization of Cx26
and Cx43 have been studied. Interestingly, Cx26 was not
detected in the normal tissue but looked upregulated and
cytoplasmic in invasive lesions of breast carcinomas [24]. The
pattern of expression was different for Cx43 with a heteroge-
neous expression at intercellular regions of the carcinoma cells
in some of the tumors studied. Laird et al. only studied Cx43
which was not detected in lobular and ductal carcinomas
whatever the grade tested [25]. The result was so clear that the
authors concluded that Cx43 would be an interesting marker
for early oncogenesis of the breast. Here, we have to emphasize
the discrepancy of results which can be obtained depending on
in situ or in vitro observations. Indeed, Cx26 was claimed to be
a putative breast-tumor suppressor gene by using a cell model
of human breast cancer [77]. Such a result is in contradiction
with in situ observations [24].
2.8. Lung cancer
Decreased expression of Cx43 has been observed in various
human and mouse lung carcinoma cell lines which exhibit
lower dye-transfer capacity than non-transformed lung epithe-
lial cells [34,78–80]. Similarly, lack of communication, as
tested by electroporation of Lucifer yellow [81], is a common
feature of human lung carcinoma cell lines or cells freshly
explanted from human lung tumors [35]. However, positive
controls for this study were fibroblasts (exhibiting GJIC) and
not epithelial cells which would be a more appropriate control.
Lack or decreased expression of connexins is not always
observed for lung cancer. In mouse, a study which compared
by competitive cDNA library screening the gene expression in
chemically-induced lung carcinomas and normal lungs did not
report any change of connexin gene expression among the 22
clones which were found to be differentially expressed [82].
This is in agreement with another study performed with
urethane-treated A/J mice. Primary cells obtained from
hyperplasias, adenomas and carcinomas of these mice exhib-
ited extensive dye-transfer even at late-stage carcinomas. The
loss of GJIC was obtained after several months in culture,
meaning that in vitro the propagation of tumor cells can lead to
gap-junction closure [83]. These results suggest that the
molecular changes that lead to the formation of the tumor in
vivo are not sufficient to interrupt gap junctions. An alternative
explanation to the loss of GJIC during the in vitro propagation
would be the selection for a few non-communicating cells that
were present in the original population. If this is true, we
cannot exclude the hypothesis that such cells might be initiated
and non-communicating stem cells as proposed by Trosko [18].
However, the decreased amount of Cx43 which was
observed in the Cx43+/ mice makes them more sensitive to
lung cancer after urethane treatment [84]. This last result tends
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prerequisite leading to a deregulated growth of lung cells.
2.9. Discussions about the models used
The in vitro and in vivo/in situ studies presented above
show that certain types of connexins may be specifically
altered in some cancers. For instance, the loss of Cx26
expression seems to be associated with the malignant
phenotype of human bladder cancer cells [19]. The loss of
Cx32-mediated GJIC (by loss of mRNA in rats or cytoplasmic
localization in humans) is associated with hepatocarcinogenesis
[31,55]. The loss of Cx43 could be a marker of human breast
cancer [25]. These results, in which different connexins seem
to be involved in cancer affecting different organs, tend to
show up a specific link between the growth regulation of one
type of tissue with one type of connexin.
However, we have to be careful about these general
conclusions. All these studies which are presented above do
not reveal a simple and general aberration of GJIC in cancer.
The picture is more complicated and seems to depend on the
type of cancer which is considered. Except the case of liver
which presents a rather homogenous picture concerning the
connexin disturbance, the involvement of connexins depends
on the model used. For instance, some discrepancies can be
observed between in situ/in vivo analysis and in vitro studies.
We may then wonder whether in vitro models such as cell lines
are good models or not for studying the involvement of
connexins in carcinogenesis. In particular, it is important to
consider if the loss of gap junctions which is observed in vitro
is actually associated with a neoplastic process, rather than
being artificially induced by extensive cell culture: as it is for
primary cells cultured from urethane-induced lung tumors [83].
Even if these cells were isolated from late-stage carcinomas,
they possess an extensive GJIC capacity immediately upon
isolation. The following propagation of these tumor cells in
culture could induce either additional alterations that can lead
to gap-junction closure or preferential in vitro clonal expansion
of non-communicating cells originally present [18,83].
Moreover, connexin expression may depend on the cell
environment. This was the case for hepatoma cells which fail to
express connexin mRNAs in culture and express Cx32 mRNA
once transplanted in vivo. However, after transplantation, Cx32
interestingly keeps being down regulated at the post-transcrip-
tional level (Cx32 immunostaining is observed in less than 5%
of the neoplastic cells in vivo) [85]. A shift of connexin
expression is also observed: these cells (9618A cells) express
Cx43 mRNA in vitro but Cx32 mRNA in vivo. This is different
with other cells (N1S1 cells) which express Cx43 mRNA
whatever their environment [85]. A similar phenomenon has
been observed for mouse skin carcinoma cell lines unable to
express Cx26 in vitro. Those cells growing as tumors in nude
mice start to express Cx26 protein [71].
In some cases, a good correlation between in vitro models
and tissues can be found for different kinds of tumors such as
human ovarian carcinomas or rat liver carcinomas. In the first
case, a lack of Cx43 expression was observed both incarcinoma cell lines [38] and in surgery pieces [39]. In the
second case, the lack of expression of Cx32 which is observed
in hepatocellular carcinomas is well correlated with the lack of
expression of this connexin in hepatoma cell lines [86]. A
similar good correlation between in vitro and in vivo models
exists for rat bladder cancer but it goes in the opposite way
concerning GJIC and remains an exception among other types
of cancer: the chemically-induced rat bladder carcinomas
exhibit an abundant expression of Cx43 and Cx26 whereas
those connexins are barely detectable in the normal bladder
tissue. Similarly, most tumorigenic rat bladder carcinoma cell
lines exhibit an extended GJIC capacity related to both Cx26
and Cx43 expression [75].
In other cases such as human breast cancer, the data
concerning Cx26 seem contradictory depending on the in vitro
and in situ models. Cx26 was found to be a tumor suppressor in
human breast cancer cells whereas it is not always detectable in
normal breast tissue and upregulated in invasive lesions of
breast carcinomas [24]. We may then conclude as S. Jamieson:
‘‘upregulated Cx26 in carcinoma cells is not necessarily
inconsistent with a tumor suppressor role for GJIC. However,
the role of gap junctions in the formation and progression of
solid human tumors is likely to be more complex than indicated
from experimental systems’’ [24]. In vitro models such as
cancer cell lines are artificial indeed, but they present the
advantage to minimize the number of uncontrolled parameters
and they can bring important answers concerning the possible
involvement of connexins in cell growth control.
3. Aberrant gap junctional intercellular communication
and cancer
Aberrant GJIC can be either found among cancer cells or
between cancer and normal cells. The lack of GJIC among
cancer cells seems to be the consequence of two major
phenomenons: either a lack of expression or an aberrant
localization of the connexin proteins. The lack of expression is
often the consequence of a lack of transcription which may be
due to hypermethylation of the connexin normally expressed.
So far, there are very few examples suggesting that such a
phenomenon does happen. The downregulation of Cx32
expression by hypermethylation of the CpG island of Cx32
gene has been observed in human renal cell carcinomas and in
a human renal cell carcinoma cell line [51,87]. The treatment of
Cx43-negative HeLa cells with 5-aza-2V-deoxycytidine resulted
in expression of Cx43, suggesting a Cx43-gene silencing via
DNA methylation [88]. However, this is not always the case
[36] and we still do not know precisely how connexin
transcription is down regulated in some cancer cells.
3.1. Cytoplasmic localization of connexins
Several studies have shown that the expression of connexins
can occur in tumor cells but are abnormally localized and
accumulate in the cytoplasm. Such observations have been
made both in vitro and in vivo and did not depend apparently
on the origin of the tumor.
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In skin, Cx43 was detected by gold particles in small gap
junctions but scattered in the cytoplasm of human basal cell
carcinomas and squamous cell carcinomas [52]. This last
observation was not made in normal skin. Similarly, Cx26
was found to be cytoplasmic in human invasive carcinomas
of the breast in more than 50% of the cases [24]. This was
also true for Cx26 in some human bladder tumors [20] and
in Sertoli cells of testis infiltrated with carcinomas in situ
[49]. In this last case, the situation is even more complex
since in Sertoli cells the Cx26 expression was induced
cytoplasmically when Cx43 expression was decreased. This
was associated to a less differentiated stage of Sertoli cells as
demonstrated by the re-expression of cytokeratin 18 [49].
The altered expression of Cx26 and Cx43 in Sertoli cells in
testes infiltrated with carcinomas in situ or seminoma
suggests that a derangement in intercellular communication
between Sertoli cells (and between Sertoli cells and germ
cells) may play a role in the resulting spermatogenic
impairment and in the proliferation and progression of
carcinomas in situ [49]. Cx32 which is normally expressed
in hepatocytes was found to be localized in the cytoplasm of
human liver tumors. Similar results were found in a human
liver tumor cell line [89]. Cx43 which is not detected in
normal hepatocytes was present in the invasive parts of the
same tumors [31]. This means that the impaired trafficking
does not depend on the type of connexin which is expressed
in liver. It appears to be a general phenomenon affecting all
connexins expressed in the same cells. The fact that a new
connexin (Cx43) appears in the invasive parts of a tumor
suggests that aberrant localization/expression of connexins
may depend on the stage of the tumor. Indeed, this was
shown in human prostate cancer. In this type of cancer, the
connexins are localized at the cell–cell contact areas in
normal and well-differentiated tumors (only Cx32 in the
normal tissue and both Cx32 and Cx43 in the tumors). But
progressively, the cytoplasmic localization of both connexins
in the undifferentiated stages is noted [42]. In a transgenic-
mouse model developing testicular tumors confined to
Leydig cells, the endosomal requestration of Cx43 is an
early event associated in situ with uncontrolled Leydig cell
proliferation before the onset of testicular tumor invasion
[90]. The cytoplasmic localization of connexins has also been
observed in chemically-induced tumors suggesting it could be
a general phenomenon of carcinogenesis. As an example, we
can cite the cytoplasmic localization of Cx32 and Cx26 in
chemically-induced rat hepatomas [58].
It is also interesting to note that the cytoplasmic localization
of connexins has been associated with invasive parts of
carcinomas. This is the case for Cx26 and Cx43 in chemical-
ly-induced rat bladder cancers [75]. Another example is about
the apparition of Cx43 in either rat and human liver carcinomas
[31,57].
3.1.2. Cytoplasmic localization of connexins in vitro
In a seminoma cell line, Cx43 was present in the trans-Golgi
network [91]. But in this last case, the induced overexpressionof the Cx43 was followed by the correct targeting of the
connexin to the membrane and by growth decrease. In other
cases, the aberrant localization of the connexins seems to be the
consequence of a wrong intrinsic mechanism of membrane
targeting since no induced overexpression of these proteins can
change this situation. This was observed in some human colon
tumor cells which express Cx43 in their cytoplasm. The
transfection of a Cx43 cDNA did not improve the membrane
localization of the Cx43 which was accumulating in the
cytoplasm without modifying the cell–cell communication
capacity tested indirectly by the lack of bystander effect [92].
The intracellular accumulation of connexins was also observed
in several prostate cancer cell lines suggesting that the impaired
trafficking of the connexins could be the major cause of GJIC
deficiency in human prostate cancer cells [93].
The cytoplasmic localization of connexins is not always
associated with abnormal or pathological situations. For
instance, a transient intracytoplasmic storage of Cx43 has been
described in uterine myocytes before parturition [94]. Similar-
ly, the cytoplasmic storage of connexins represents a normal
physiological process during spermatogenesis [91]. Curiously,
in this last system, the storage of the connexins is associated
with the presence of a 70-kDa isoform of Cx43. It has been
argued that the cytoplasmic storage of Cx43 in the germ cells
would play a role in cell growth control: it could allow
spermatogonial proliferation at the beginning of a new wave of
spermatogenesis before the recruitment of Cx43 to the plasma
membrane [95]. The relationship between the localization of
Cx43 and growth control is confirmed by the fact that its
relocalization in the membrane is associated both with the
induction of GJIC and decreased cell growth in vitro [91]. The
association between Cx43 localization in the membrane and
growth regulation is even reinforced by the fact that lindane
induces a delocalization of Cx43 from the membrane to the
cytoplasm and consequently a loss of GJIC [96]. Such a
phenomenon was first observed by treating rat liver epithelial
cells with lindane [97]. Apparently, lindane induces Cx43
phosphorylation and cytoplasmic localization in endosomes by
activation of ERK/mitogen-activated protein kinase pathway
[98].
It is interesting to note that even a nuclear localization of
connexins has been reported. This is the case for Cx43 in rat
liver epithelial cells transformed by either src or neu
oncogenes [99]. Such a phenomenon seems to depend on
the types of oncogenes which are activated since it is not
observed when those cells are transformed by ras associated or
not with an activated myc oncogene even if GJIC and
phosphorylation of Cx43 are both decreased in all cases
[99]. More recently, it was shown that the inhibition of growth
of HeLa cells was induced by the carboxy-terminal part of
Cx43 which was localized in the nucleus of the cells [100].
The reason for such a localization in the nucleus is not known.
This may suggest that Cx43 could be involved in the control
of transcription but this has not been proved yet [99].
However, without going so far, it tends to demonstrate that
the formation of channels may not be always required for
growth inhibition [100].
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The mechanisms leading to the aberrant localization of the
connexins in the cytoplasm are not known. It was suggested
that it is due to a cell – cell recognition impairment.
Carcinomas often exhibit a decreased expression and/or
aberrant localization of E-cadherin, a major transmembrane
protein involved in the cell–cell recognition process of
epithelial cells. Several studies have shown that the forced
expression of E-cadherin in cell lines induces a more
epithelial phenotype to the cells which may be accompanied
by gap-junction restoration [101]. E-cadherin seems to permit
a correct addressing of connexins to the cell membrane [73].
It has even been argued that such a process is the
consequence of a hyperphosphorylation of the Cx43 mediated
by the cadherin expression [102]. More recent data reinforce
the idea of a possible involvement of cell–cell recognition in
connexin localization: for instance, the induction of alpha-
catenin favorizes the membrane relocalization of the connex-
ins in human prostate cancer cell lines [93]. Such data
emphasize the fact that the disturbance of GJIC would be the
consequence of an aberrant cell–cell recognition process.
However, other examples do not go in such a direction. For
instance, it was suggested that the cytoplasmic localization of
Cx32 in human liver carcinomas could be due to a lack/
decreased expression of E-cadherin but this protein is
expressed in carcinomatous cells as in non-carcinomatous cells
suggesting that connexin localization can be controlled by
other processes [63].
3.2. Lack of heterologous gap-junctional intercellular
communication
Several coculture experiments indicate that cancer or
transformed cell lines had little or no GJIC capacity with their
non-transformed counterparts. This was observed in different
cell systems as BALB/c 3T3 cells [103], human lung
carcinoma cells [34], mouse skin cells [70] and rat oesophageal
cells [76]. Such an observation was even made if the
tumorigenic cells do exhibit extensive intrinsic GJIC [76].
Similar results were also obtained on transformed foci which
were raised from a normal cell population by oncogene
transfection or chemical treatment [104]. This last approach
may seem less artificial than mixing cancer cells and normal
cells in the same dishes.
More convincingly, such results that could have been
estimated as an in vitro artefact were also observed by using
in vivo models. For instance, a selective lack of heterologous
GJIC has been observed between neoplastic and surrounding
normal cells by microinjecting fluorescent dye in fresh pieces
of rat and human liver tissue [31,52]. It has to be noted that in
both cases (rat and human), the dye-transfer assay revealed a
strong reduction of the GJIC capacity compared with non-
tumoral surrounding liver tissue. The lack of heterologous
GJIC occurs in most of GST-P positive foci in rats [52] and is
related to a decreased homologous GJIC capacity in those foci.
Similarly, all human liver tumors tested by dye-transfer assayrevealed a strong reduction in GJIC compared with non-tumor
surrounding liver tissue [31]. In this last case, the heterologous
lack of GJIC was probably due to the presence of a connective
capsule around the tumors [31].
Lower GJIC capacity in adjacent tissues surrounding the
tumor may be also another cause of the lack of GJIC between
the cells of the tumor and their non-tumoral conterparts [31].
Such a reduction of connexin expression in the adjacent non-
neoplastic tissues has also been observed in skin tumors [67].
Actually, we do not know whether such a lack of GJIC
between normal and tumor cells is a common feature in human
cancer. This lack of knowledge is due to the lack of
sophisticated in situ approach that would permit to estimate
whether GJIC does occur or not between cancer cells and
normal cells in biopsies. Moreover, even if techniques would
be suitable for such estimations, the lack of a clear frontline
between the tumor and the normal surrounding tissues would
prevent to make it. Therefore, it is impossible to estimate
whether the lack of communication between tumor and non-
tumor cells play a role in carcinogenesis by using in situ
approaches.
We can simply hypothesize that it may play a role in growth
control of cancer cells by referring to in vitro experiments in
which re-induction of GJIC between the two cell types was
able to prevent the growth of transformed cells [105]. This
hypothesis is even reinforced by the fact that the growth
inhibition of transformed cells correlates with their capacity to
communicate with normal cells [106]. Such observations made
GJIC suspected to be actively involved in growth control
[106,107]. However, the situation is more complicated than it
appears because GJIC is not obligatory required for promoting
an heterologous growth control. Indeed, some studies have
shown that non-transformed cells may completely suppress the
growth of neighboring transformed cells without requiring gap
junctions [108]. Therefore, at least in some cases, it seems that
a direct intercellular contact is required for growth control even
if it is not accompanied by the establishment of GJIC. We may
then argue that molecules involved in direct cell –cell
interaction may have such a role as they have for maintaining
some cell differentiation [109].
3.3. Connexin mutation and cancer
Two different sorts of observations argued for possible
mutations of connexin genes in cancer. First, the aberrant
localization of connexins in cancer cells could have been the
consequence of specific mutations since in vitro experiments
have shown that mutations affecting connexins (which are
associated with human genetic diseases) could accumulate into
the cytoplasm. Secondly, several experiments have shown that
connexins act as tumor suppressors which are classically
mutated in cancers [6]. Consequently, the research of mutations
has been performed in several types of connexins.
3.3.1. Cx37
Several studies on Cx37 mutations have been initiated from a
report mentioning that mutated Cx37 is at the origin of shared
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of mouse Lewis lung carcinoma cell lines (3LL and CMT cell
lines) [110]. However, despite this previous result, DNA from
3LL and CMT cells did not exhibit any Cx37 mutation [111].
Since Cx37 is mostly expressed in endothelial cells, endothe-
lial-derived tumors have been studied in order to see whether
Cx37 mutations were involved in their genesis. Indeed, Cx37
mutations were detected in hepatic angiosarcomas (2 samples
out of 22) from rats treated by vinylchloride. Base substitutions
were detected at codon 166 (CGA to CGC) and codon 168
(GGG to GAG) in very few tumors (3/22 samples). The first
mutation (3/22 samples) was silent (arginin) and the second was
changing a glycine into a glutaminic acid. Cx37 proteins were
detectable in endothelial cells of normal liver by immunohis-
tochemical analysis, but none of these induced angiosarcomas
showed Cx37-positive spots. These results suggest that Cx37-
mediated GJIC may be disturbed in most of these angiosarco-
mas. However, this mutation is probably not crucial for
angiosarcoma development since it was found in only one out
22 samples [112]. In addition, a silent polymorphism was
detected at codon 88 [112]. In human, mutations affecting the
Cx37 (proline-serine change at codon 319) were found in
hemangiosarcomas. Actually, this was a polymorphism of the
gene since the mutation was also found in the normal tissue of
the same patients. In 84 normal donors, this polymorphism
exhibited different ratios (Pro/Pro: 65.5%; Pro/Ser: 23.8%; Ser/
ser: 10.7%) and, even if it does not seem to be correlated to
angiosarcomas, the authors were questioning whether Ser319
predisposes to this type of cancer [113]. Another polymorphism
could affect the Cx37 gene at codon 130 converting valine into
isoleucine. This was found in patients suffering of breast cancer
(3 tumors out of 18) and lung cancer (2 tumors out of 8) but also
in the normal tissue of the same patients [114].
3.3.2. Cx32
The aberrant cytoplasmic localization of Cx32 in human
hepatocellular carcinomas is not associated with any mutation in
the coding region of the Cx32 gene [31]. Similar lack of
mutation in Cx32 has been reported in human stomach tumors
and human colon sporadic adenocarcinomas even if no study
was performed about the Cx32 expression/localization in those
samples [115,116]. In rats, only one chemically-induced
hepatocellular carcinoma out of 12 exhibited a mutation affec-
ting codon 220 of Cx32 [117]. This last mutation (His to Arg)
was functionally silent, as tested by dye-transfer assay in HeLa
cells, and responded normally to various stimuli (cAMP, 12-O-
tetradecanoylphorbol-13-acetate, lysophosphatidic acid) [117].
3.3.3. Cx43
More convincing data about a possible correlation between
connexin mutations and cancer concerned Cx43. Cx43 is
specifically mutated (but not Cx32) in human colon sporadic
adenocarcinomas [116]. All these mutations were associated
to advanced stages of progression of the tumors; they were
located in the carboxy-terminal part of Cx43 and led to a shift
of the reading frame of the gene. Interestingly, the expression
of the mutated Cx43 was restricted to the invasive structuresof the tumors. It is not known yet what could be the
functional consequences of such mutations on the Cx43
function and if there are really associated with the invasive
phenotype of the tumors (see the part 4 of this review). This
mutational phenomenon is not a general one affecting Cx43
since the lack of detectable transcripts in ovarian carcinoma
cells was not the consequence of deletions or rearrangement
in the Cx43 gene [38]. Similar conclusion was made for
murine and human lung carcinoma cell lines exhibiting
limited ability for dye-transfer and Cx43 expression [34].
No mutation of Cx43 gene was found in mouse skin tumors
induced chemically [118].
3.3.4. Cx31.1
In head and neck squamous cell carcinomas a 10-fold
downregulation of Cx31.1 as well as mutations in the TGF-
beta-receptor-II were reported [119]. Therefore, the research of
mutations affecting the Cx31.1 gene has been performed
without any success meaning that no Cx31.1 mutation is
involved in laryngeal tumorigenesis [119]. Only a silent
polymorphism has been observed in some tumors [119].
3.3.5. Other aspects and conclusions about connexin gene
mutation and cancer
Another aspect to consider is that the lack of connexin
expression in cancer cells could be the consequence of
mutations affecting non-coding portions of the connexin genes.
Such portions are known to play a crucial role in the regulation
of expression of the connexins. This is not only the case for the
promoter region of the gene but also for the newly discovered
IRES (Internal Ribosomal Entry Site) elements of major
connexin genes such as Cx26, Cx32 and Cx43 [120–122].
Indeed, the involvement of such regions has been observed for
some human genetic pathologies which are associated with
altered connexin function. Most examples come from the X-
linked Charcot–Marie–Tooth (CMTX) disease known to be
associated with Cx32 defects [123]. If most mutations of the
CMTX disease are located in the coding regions of the Cx32
gene, some were also found in the nerve-specific Cx32
promoter or in the 5V-untranslated region of the Cx32 mRNA
[121,124,125]. Interestingly, the defective function or expres-
sion of Cx32 in such patients has not been shown yet to be
related to a higher risk of tumorigenesis in the tissues where
this connexin is normally expressed even for patients exhibit-
ing no Cx32-coding region [126].
Previous studies on tumor-suppressor or cancer-associated
genes have shown that tumorigenesis follows a two-hit
mechanism that involves both gene mutations and loss of the
second allele. In principle, tumor-suppressor genes include two
classes: class I, in which loss of function results from mutation
or deletion of DNA and class II, in which loss of function is
from a block of expression. If connexins are putative tumor
suppressors, they would belong to the class II which is
assumed to be regulated by a different suppressor gene that
lost its function by mutation or deletion [77]. This last case can
be related to the altered expression of connexin-controlling
transcription factors such as the hepatocyte nuclear factor 1a
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downregulated in liver tumors [128–130].
However, the reality seems to be more complex. Indeed,
when only one allele of a connexin gene is mutated, it may
happen that the non-functional form of the connexin encoded
by the mutated allele does prevent the function of the normal
one. This dominant-negative effect has been indeed observed
through in vitro approaches for some connexin mutations
detected in human pathologies [131]. Recent data tend to show
that such dominant mutations affecting Cx26 and involved in
the keratitis– ichthyosis–deafness (KID) syndrome could
increase the risk of epidermal carcinogenesis [132]. This last
example suggests that connexins could be also a particular
class I suppressor gene for which the loss of function may
result from the mutation of only one allele of the gene.
4. Connexins and metastasis
Metastasis is a complex phenomenon where cell dissociation
is followed by tissue invasion, transport of metastatic cells
through the blood stream, extravasation and formation of
secondary tumors by colonization of foreign organs. At least
in two crucial steps of this dramatic succession of events,
cellular interactions are heavily involved: (1) cell dissociation
leading to invasion and (2) recognition between tumor cells and
endothelial cells leading to diapedesis and the formation of
secondary tumors. It is probable that in these two events, gap
junctions in combination with cell adhesion molecules can
affect the metastatic potential. This has been hypothesized for
long time but a clear picture has not yet emerged [133,134]. In
this part of this review, we will consider the succession of these
events only from the point of view of gap junctions.
4.1. Cell dissociation and invasion
The common hypothesis about a possible involvement of
connexins in metastasis directly comes from the reduced
number of gap junctions which is observed during tumor
progression. There are evidences suggesting that the loss of
GJIC correlates with the metastatic potential. Even if this is not
always true, several models do exhibit such a correlation. This
was shown in rat mammary adenocarcinoma cells [135]. The
observed decrease of GJIC might be correlated to a decreased
expression of the connexins. For instance, mice treated with
dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) exhibit a clear reduction of Cx26 and
Cx43 in the invasive sites of the induced squamous cell
carcinomas [68]. Similarly, Cx43 mRNAwas not detected in a
highly metastatic human lung carcinoma cell line [136]. A
similar observation was made in breast cancer where a
correlation was found between metastatic potential and the
decrease of Cx43 gene expression [137]. Restoration of GJIC
has been observed in a metastatic human breast carcinoma cell
line transfected with the breast metastasis suppressor 1
(BRMS1) cDNA. It increases Cx43 expression and reduces
Cx32 expression, resulting in a gap-junction phenotype more
similar to the normal breast tissue [137].However, the common assumption that connexin expression
is inversely correlated to metastatic potential is probably too
simple. Indeed, Cx26 was found to be still expressed and even
upregulated in invasive human breast carcinomas (15 samples
out of 27) but the cytoplasmic localization and its heterogeneity
is not compatible with an efficient establishment of GJIC [24].
The wrong localization of connexins could be the consequence
of the cytoplasmic localization (or lack of expression) of cell
adhesion molecules, such as E-cadherin, which is frequently
observed in carcinomas. This phenomenon which is thought to
be a prerequisite for cell invasion probably interferes with the
gap-junction formation. This can be assumed by the accumu-
lated evidences in the past showing that E-cadherin expression
favorizes the establishment of GJIC [73,101]. It is then easy to
consider that the lack of cell recognition in the primary tumor
prevents the establishment of GJIC and may facilitate the
invasion process.
Another aspect to consider is the cell-substrate connections.
In parallel with E-cadherin lack of function, detachment from
the basal membrane is often observed as a prerequisite to cell
invasion. Some data suggest that these types of interactions,
such as a3h1–laminin 5 interaction, could be important for
maintaining GJIC by regulating the intracellular protein
trafficking involved in assembly of gap junctions. This process
would involve a Rho-mediated signaling [138]. According to
these results, the lack of such interactions could prevent the
renewal of gap-junction plaques between cells. Even if it is not
well documented yet, another reason for the loss of GJIC and
wrong localization of connexins could be mutations affecting
connexin genes (see part 3.3 of this review). Mutations of
connexins have been indeed observed in invasive portions of
some tumors. This is the case for Cx43 which is mutated in
invasive regions of colon adenocarcinomas [116].
Whatever the molecular events responsible for GJIC
decrease are, the subsequent loss of cooperation between
neighboring cells is believed to lead to cell heterogeneity and
cell dissociation in the invasive parts of the primary tumor
[139]. Does it mean that the invasive phenotype of tumor cells is
not compatible with GJIC? Probably not since gap-junctionally
coupled tumor cells can invade embryonic chicken heart
fragments (ECHF), whereas non-coupled tumor cells, like
HeLa cells, did not [140]. Moreover, invasion of ECHF is
made possible when HeLa cells were rendered communicating
after transfection of connexin cDNAs. This phenomenon seems
to be independent of the establishment of heterotypic GJIC
between transfected HeLa cells and chicken heart cells. If the
transfected connexins (Cx31, Cx40 and Cx43) did not modify
the replication rate of the HeLa cells, they were differently
invasive; Cx43-expressing cells being the most invasive ones in
this experimental model [141]. These in vitro data support some
in vivo data in which the abnormally-augmented expression of
Cx26 is responsible for the enhanced spontaneous metastasis of
mouse BL6 melanoma cells. This phenotype seems to be
specific to the Cx26 function since the exogenous expression of
a dominant-negative form of Cx26 or the chemical inhibition of
Cx26-mediated GJIC (by a oleamide derivative) prevents the
spontaneous metastasis of the BL6 cells [142].
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Extravasation of malignant cells often involves trans-
endothelial migration (diapedesis) into tissues prior to forming
secondary tumors. In contrast to diapedesis of leukocytes
during inflammatory responses, little is known about the
molecular mechanisms that regulate tumor–cell diapedesis.
A possible explanation could be the establishment of
heterocellular GJIC between tumor cells and endothelial cells.
Such a phenomenon which has been observed for breast tumor
cells and endothelial cells may be an important regulatory step
during metastasis [143]. This was also observed in mouse
melanoma cells expressing Cx26. Increasing the Cx26 expres-
sion by transfection or inhibiting its function by a dominant-
negative variant resulted as a good correlation between GJIC and
metastatic capacities of the melanoma cells [144]. This
observation correlates with the level of Cx26 expression which
is upregulated in melanoma cells invading the dermis compared
with the melanoma cells residing in the basal layer, in human
samples [144]. It was concluded that Cx26 plays a role in
intravasation and extravasation of tumor cells through heterol-
ogous gap junction formation with endothelial cells [144].
As a parenthesis, we see here a contradictory observation.
We have seen in the previous paragraph that the decrease of
GJIC could play a role in cell dissociation and invasion. Here,
upregulation of Cx26 is observed in invasive parts of the
human melanoma. This apparent contradiction means that the
cellular event we are reviewing may be different depending on
the connexin which is expressed or the cell type and the tumor
type which are considered. At least, the connexin type may be
important to consider since upregulation of Cx26 was observed
in invasive parts of both breast cancer and melanoma in human
samples [24,144]. Without going further in speculation, it is
interesting to note that Cx26 upregulation is observed in some
cases where cells proliferate (psoriasis, etc.).
If the establishment of gap junctions is involved in the
extravasation process, it is probably just a part of a more
complex phenomenon in which paracrine communication,
endothelial cell adhesion and gap junctions are all involved.
At least a clear interdependence has been observed between
endothelial cell adhesion and communication of lung-metastatic
cancer cells. It was shown that the level of coupling at focal
adhesion contacts depends on sufficient amounts of Cx43 by
both cell partners and, in a rate-limiting fashion, on the
expression level of the receptor/ligand pair that mediates
adhesion between tumor cells and the endothelium. Significantly
increased adhesion and communication levels in highly lung-
metastatic carcinoma cells imply a role of gap-junctional
coupling in cancer metastasis, presumably by facilitating
extravasation [145].
An interesting scenario describing possible molecular
mechanisms involved in this complex process came from
studies on HTLV-1, the human T-cell lymphotropic virus type
1, which is the causative agent of adult T-cell leukaemia/
lymphoma (ATL). ATL-derived leukemic cells communicate
with endothelial cells through both angiogenic-factor mediated
paracrine stimulation and direct gap-junction-mediated hetero-cellular communication [146]. The HTLV-1 transactivator Tax
seems to play an important role in this interaction by inducing
the transcriptional activation of VEGF promoter and Cx43
promoter and by increasing the heterotypic communication
[147]. This dual interaction between ATL-derived cells and
endothelial cells induces the production of matrix metallopro-
teinases by endothelial cells which leads to the degradation of
subendothelial basement membrane and retraction of endothe-
lial cells, allowing then the extravasation of ATL-derived cells
[147].
Local disturbance of the gap-junction pattern among
endothelial cells may be also involved. For instance, it was
shown that coculturing human breast cancer cells with
endothelial cells leads to a rapid and transient inhibition of
GJIC between the endothelial cells. Such a phenomenon is
probably the consequence of interactions between the two cell
types which leads to the tyrosine phosphorylation and
functional inhibition of the endothelial Cx43 [148]. This local
disturbance of GJIC among endothelial cells may be important
since, in a model using human oral squamous cell carcinoma
cells and rat lung endothelial cells, the development of cell-to-
cell interactions, e.g., gap junctions and tight junctions in
endothelial cells, by chemical treatment (malotilate) results in
the inhibition of invasion by the tumor cells [149].
Local disturbance of GJIC between endothelial cells may be
the consequence of paracrine factors produced by the tumor
cells. Such a phenomenon happens during tumor–stroma
interaction of skin cells: the homologous GJIC of the stromal
fibroblasts is inhibited by paracrine acting factors of epithelial
tumor cells. In this model, the decrease of GJIC is due to a post-
translation modification of Cx43 but not to a change of
expression of Cx43 [150]. This result correlates with the
observation of aberrant Cx43 mRNA expression in adjacent
normal lung tissue, around nodal micrometastasis of non-small
cell lung cancers, which is a consequence of methylation of the
Cx43 promoter [151].
Some work also suggested that gap junctions could elicit
particular tissue targeting for the metastatic cells. It was said
that preferential metastasis could be the consequence of the
formation of heterotypic gap junctions between metastatic cells
and cells of the target tissue. For instance, the formation of
heterotypic gap junctions between a human breast carcinoma
cell line and a human osteoblastic cell line was suggested to
explain why a large extent of metastasis from breast cancers
occurs in bone [152]. This was reinforced by the fact that
heterotypic GJIC was even larger than homotypic GJIC
between the carcinoma cells [152]. Moreover, contrary to the
parental cells, transfection of a breast metastasis inhibitor,
BRMS1, into the breast cancer cells increased homotypic GJIC
but not heterotypic GJIC [152].
Finally, in order to close this part concerning connexins and
metastasis, just a few words about the direct or undirect use of
connexins as putative therapeutic tools against metastasis. It is
interesting to mention that regression of established murine
carcinoma metastases following vaccination was obtained with
tumor-associated antigen peptides which were in fact derived
from a mutated Cx37 gap-junction protein (see Section 3.3.1 of
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oleamide derivative able to inhibit specifically the Cx26-
mediated GJIC in melanoma cells blocks partially the
metastasis of these cells in mice [142].
5. Conclusions
A question which is often asked is whether the lack of
connexin expression is a prerequiste for the loss of growth
control. In other words, the different questions we may ask are:
does the lack of expression of a specific connexin:
– induce a deregulated cell growth?
– modify the pattern of expression of genes involved in cell
growth control?
– increase the susceptibility to cell transformation (at the
cellular level) or carcinogenesis (at the organism scale)?5.1. Connexin expression as a prerequisite for the loss of
growth control
The recent use of transgenic animals such as connexin-KO
mice did not permit in the last years to bring some clear
answers to these specific questions. Indeed, if fibroblasts
isolated from Cx43-null mice exhibited a higher growth rate
[155], it was not the case for all cell types. For instance,
primary cultures of astrocytes isolated from Cx43-null mice
grow slower than their wild-type counterparts despite a lack of
GJIC as tested by dye-transfer [156]. Moreover, if we presume
that glial fibrillary acidic protein and S100 are good markers
for estimating glial differentiation, the differentiation of the
cells was not modified by the lack of the most abundant
connexin of astrocytes [156]. This is in agreement with the fact
that brains of Cx43-null mice are macroscopically normal and
display a pattern of cortical lamination that is not detectably
different from wildtype siblings [157]. It has been argued that
this lack of macroscopically effect is due to the presence of a
variety of other types of connexins (Cx26, Cx30, Cx40, Cx45,
Cx46), detected by various techniques and at various times of
culture, in those Cx43-null astrocytes [157]. Therefore, it was
concluded that astrocyte gap junctions can be formed by
various types of connexins and that the metabolic and ionic
coupling provided by these diverse gap-junction types may
functionally compensate for the absence of the major astrocyte
gap-junction protein in Cx43-null mice [157]. This is actually
contradictory with the fact that no dye transfer was observed in
those Cx43-null astrocytes, contrary to their wild-type counter-
parts [156]. It is possible then that dye-transfer is not an
appropriate approach to answer to this question, that more
subtle GJIC mediated by compensating connexins is involved
at different periods of the brain development. It is also possible
that primary cultures may be an artefactual model depending
on growth factors which are present in the medium.
Observing the cancer susceptibility of the whole organism
lacking a specific connexin may be a better approach. A higher
tumor rate has been indeed observed in such animals meaning
that the lack of specific connexins may be a prerequisite fortumor formation. For instance, a higher incidence of liver
neoplasms (spontaneously- or chemically-induced) was shown
in mice lacking Cx32 which is the major connexin usually
expressed in hepatocytes [60]. The intraperitoneal injections,
two weeks after birth, of DEN led, after 1 year, both to more
liver tumors in Cx32-deficient mice than in controls [60]. Since
Cx32 has a stabilizing effect on Cx26, the lack of Cx32 is
probably emphasized by the decrease of Cx26 in hepatocytes.
Indeed, comparison of dye spreading in connexin-32-deficient
versus wild-type liver revealed a 96% decrease in connexin-32-
deficient tissue which would not be reached without a
significant decrease of Cx26 [158].
Similarly, the deletion of one allele of a connexin gene may
be sufficient to induce a higher susceptibility to tumor
formation: for instance, the deletion of one allele of the Cx43
gene (and subsequent decrease of Cx43 expression) clearly
favors the carcinogenic effect of urethane administration and
results in a higher susceptibility to lung adenoma formation in
mice [84]. In vivo, the lower Cx32 mRNA amount in female
rats may also explain their higher sensitivity to liver tumors
induced by hexachlorobenzene [61]. This Cx32 transcription
difference between females and males seems to be controlled
by ovarian hormones since ovariectomy abolished any differ-
ence between them [61]. All these examples tend to show that a
decreased level of expression of a connexin may be a
prerequisite for tumor growth.
5.2. The effect of a lack of connexins on gene expression
Very few studies have been performed on this topic so far.
By using high-density cDNA microarrays in Cx43-null
astrocytes, the analysis of gene expression revealed 4,1% of
the 4998 quantifiable spots having significantly decreased
hybridization compared to controls and 9,4% of the spots
showing significantly higher hybridization. These different
spots corresponded to RNAs encoding 252 known proteins
including transcription factors, channels and transporters, cell
growth and death signals, enzymes and cell adhesion mole-
cules. These data indicate a surprisingly high degree of impact
of deletion of Cx43 on others astrocytes genes: gap junction
gene expression alters numerous processes in addition to
intercellular communication [159,160]. Such experiments are
still preliminary and it is obvious they should be extended to
other types of connexins. However, those preliminary results
concerning Cx43 and murine astrocytes reinforce the idea that
gap junctions are involved in the regulation of gene expres-
sions which are crucial for the cell phenotype and in particular
for the control of cell growth.
Contrary to classical tumor suppressor genes which are
known to control very specific molecular mechanisms, it seems
that connexins do control a large panel of processes which may
lead to cancer if they are not functioning properly.
5.3. General conclusions
Through all the examples which are cited in this review, we
may conclude that connexins do play probably a role in
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during 40 years, suggest that it is the case. Depending on the
models which have been used, it is obvious that defective gap
junctions may tend to be either a prerequisite (as suggested by
some studies performed on connexin-KO mice) or a conse-
quence of the tumor development. In this last case, the
decreased expression of connexins or their aberrant cellular
localization can be related to some tumor progression stages.
Nevertheless, whatever the deficient gap junctions are a
prerequisite or a consequence of the tumor formation, they
seem to give a strong impact on the development of solid
tumors. As we have seen, they probably play also a crucial role
in the late stages of cancer but at different levels; the invasion
stage being mostly associated with a loss of function of the gap
junctions, whereas a gain of function may characterize the
metastasis stage.
Still, very few is known about the molecular mechanisms
regulated by the gap junctions and which are responsible for
growth control, invasion and metastasis. Understanding these
molecular mechanisms may depend on the answer to the two
fundamental and following questions:
Is such a regulation made through the establishment of
GJIC? If yes, the understanding of the molecular mechan-
isms which are involved in growth control will depend on
the identification of molecules passing through gap junc-
tions. Such an identification is one of the biggest challenge
for the researchers working in the domain of the gap
junctions.
Is the cell growth regulated by connexins but independently
of GJIC? If yes, what are the other functions of the
connexins? Do they have these other functions through
either specific interactions with particular proteins of the
cytoplasm or specific localizations inside the cells? Do these
other functions make them able to switch off or switch on
signaling pathways involved in cell growth control?
The role of connexin is probably complex and still new
theories emerge trying to bring some answers [18]. New
insights concerning the direct control of gene expression by
connexins are coming out, especially from connexin-trans-
fected cells and more recently from connexin-KO mice. We
may also expect interesting data coming from conditional
connexin-KO mice. The induced lack of expression of a
specific connexin in an adult tissue could bring interesting
conclusions about the role of that connexin on cell differen-
tiation and growth control. Such a strategy would shut down
the compensation phenomenon which is observed during
embryogenesis and permit the replacement of the lacking
connexin by others [157]. Connexin studies should also be
extended to the human situation by using primary cultures of
tumor cells and not only cell lines or animal models which
have their own characteristics.
Now, let us imagine for a while the domain of gap junction
research as a tree. The common trunk would correspond to the
discovery of gap junction, their molecular structure, the
diversity of connexins as members of a multigene family,etc. From that trunk, emerging branches would characterize the
accomplished progresses concerning the involvement of gap
junctions/or connexins in physiological and/or pathological
events. Some of these branches could eventually grow up to
the full understanding of their role in such events. Newer
branches of that tree have been growing quickly establishing
in very recent years a clear association between certain
connexins, their function and particular types of human
diseases. Branches elucidating physiological roles from studies
using connexin-KO mice as models were also growing very
rapidly during the last decade. Paradoxically, there is not yet a
so rapid growth of knowledge about the oldest branch, which
emerged about 40 years ago and associates one of the most
extended human diseases, cancer, with gap junctions. Over
these past four decades of research, it has become clear that
connexins and GJIC are involved in cancer and cellular growth
control. However, there does not appear to be a single,
consistent result or mechanism. This is most likely due to the
diversity of connexins and gap-junction channel properties,
and the cell types and context in which they are expressed.
Future research will undoubtedly help to clarify these
ambiguities and lead to a better understanding of the
mechanisms which are involved.Acknowledgements
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